Frequent BRAFV600E mutation has no effect on tumor invasiveness in patients with Langerhans cell histiocytosis

Wei,Rui; Wang,Zhongqing; Li,Xiaolin; Shu,Yigang; Fu,Bin

doi:10.3892/br.2013.62

May-June 2013 Volume 1 Issue 3

Full Size Image

Journals

International Journal of Molecular Medicine

International Journal of Molecular Medicine is an international journal devoted to molecular mechanisms of human disease.

International Journal of Oncology

International Journal of Oncology is an international journal devoted to oncology research and cancer treatment.

Molecular Medicine Reports

Covers molecular medicine topics such as pharmacology, pathology, genetics, neuroscience, infectious diseases, molecular cardiology, and molecular surgery.

Oncology Reports

Oncology Reports is an international journal devoted to fundamental and applied research in Oncology.

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine is an international journal devoted to laboratory and clinical medicine.

Oncology Letters

Oncology Letters is an international journal devoted to Experimental and Clinical Oncology.

Biomedical Reports

Explores a wide range of biological and medical fields, including pharmacology, genetics, microbiology, neuroscience, and molecular cardiology.

Molecular and Clinical Oncology

International journal addressing all aspects of oncology research, from tumorigenesis and oncogenes to chemotherapy and metastasis.

World Academy of Sciences Journal

Multidisciplinary open-access journal spanning biochemistry, genetics, neuroscience, environmental health, and synthetic biology.

International Journal of Functional Nutrition

Open-access journal combining biochemistry, pharmacology, immunology, and genetics to advance health through functional nutrition.

International Journal of Epigenetics

Publishes open-access research on using epigenetics to advance understanding and treatment of human disease.

Medicine International

An International Open Access Journal Devoted to General Medicine.

May-June 2013 Volume 1 Issue 3

Full Size Image

Article

Frequent BRAFV600E mutation has no effect on tumor invasiveness in patients with Langerhans cell histiocytosis

Authors:
- Rui Wei
- Zhongqing Wang
- Xiaolin Li
- Yigang Shu
- Bin Fu
View Affiliations / Copyright

Affiliations: Department of Radiation Therapy, Xiangya Hospital, Central South University, Changsha, Hunan 410008, P.R. China, Department of Ultrasonography, Xiangya Hospital, Central South University, Changsha, Hunan 410008, P.R. China, Department of Haematology, Xiangya Hospital, Central South University, Changsha, Hunan 410008, P.R. China
Pages: 365-368
|
Published online on: January 25, 2013

https://doi.org/10.3892/br.2013.62
Expand metrics +

Abstract

The oncogenic BRAFV600E mutation in patients with Langerhans cell histiocytosis (LCH) has recently been reported. However, the reported frequencies were significantly inconsistent and were based on studies of populations of western ethnic origin. The aim of this study was to identify the presence of BRAFV600E mutation in a cohort of Chinese LCH patients and to determine its association with clinicopathological characteristics. Blocks were retrieved from 52 LCH patients and 12 samples were obtained from blood or bone marrow. These were tested for BRAFV600E by directly sequencing the entire exon 15 of the BRAF gene. To demonstrate the relationship between BRAFV600E and invasiveness of LCH, the single or multiple systems classification was used. BRAFV600E was the only genetic abnormality within exon 15 of the BRAF gene in patients with LCH. Its incidence was 56%, similar to that reported in a United States study, but higher than that reported in German studies. Additionally, the frequencies were similar between patients with single system diseases and those with multiple system diseases. Results of this study showed that BRAFV600E was present in a large number of the Chinese LCH patients, confirming the neoplastic nature of LCH. The frequency was similar to that of the USA study but distinctly higher than that from the Europe studies. No additional mutation were identified besides BRAFV600E. This mutation did not closely correlate with clinical severity or classification. The finding of BRAFV600E in LCH has important implications for both molecular diagnosis and targeted personalized therapy.

View Figures

View References

1	Stalemark H, Laurencikas E, Karis J, Gavhed D, Fadeel B and Henter JI: Incidence of Langerhans cell histiocytosis in children: a population-based study. Pediatr Blood Cancer. 51:76–81. 2008. View Article : Google Scholar : PubMed/NCBI
2	Haupt R, Minkov M, Astigarraga I, et al: Langerhans cell histiocytosis (LCH): Guidelines for diagnosis, clinical work-up, and treatment for patients till the age of 18 years. Pediatr Blood Cancer. 60:175–184. 2012.PubMed/NCBI
3	Xu X, Liu WP, Yang QP, et al: Langerhans cell histiocytosis: a clinicopathologic and immunohistochemical analysis of 258 cases. Zhonghua Bing Li Xue Za Zhi. 41:91–96. 2012.(In Chinese).
4	Yuasa M, Fujiwara S, Oh I, et al: Rapidly progressing fatal adult multi-organ langerhans cell histiocytosis complicated with Fatty liver disease. J Clin Exp Hematop. 52:121–126. 2012. View Article : Google Scholar : PubMed/NCBI
5	da Costa CE, Szuhai K, van Eijk R, et al: No genomic aberrations in Langerhans cell histiocytosis as assessed by diverse molecular technologies. Genes Chromosomes Cancer. 48:239–249. 2009.PubMed/NCBI
6	Bechan GI, Egeler RM and Arceci RJ: Biology of Langerhans cells and Langerhans cell histiocytosis. Int Rev Cytol. 254:1–43. 2006. View Article : Google Scholar : PubMed/NCBI
7	Filipovich A, McClain K and Grom A: Histiocytic disorders: recent insights into pathophysiology and practical guidelines. Biol Blood Marrow Transplant. 16:S82–S89. 2010. View Article : Google Scholar : PubMed/NCBI
8	Badalian-Very G, Vergilio JA, Degar BA, et al: Recurrent BRAF mutations in Langerhans cell histiocytosis. Blood. 116:1919–1923. 2010. View Article : Google Scholar : PubMed/NCBI
9	Sahm F, Capper D, Preusser M, et al: BRAFV600E mutant protein is expressed in cells of variable maturation in Langerhans cell histiocytosis. Blood. 120:e28–e34. 2012. View Article : Google Scholar : PubMed/NCBI
10	Satoh T, Smith A, Sarde A, et al: B-RAF mutant alleles associated with Langerhans cell histiocytosis, a granulomatous pediatric disease. PLoS One. 7:e338912012. View Article : Google Scholar : PubMed/NCBI
11	Roring M and Brummer T: Aberrant B-Raf signaling in human cancer - 10 years from bench to bedside. Crit Rev Oncog. 17:97–121. 2012.PubMed/NCBI
12	Allen CE, Li L, Peters TL, et al: Cell-specific gene expression in Langerhans cell histiocytosis lesions reveals a distinct profile compared with epidermal Langerhans cells. J Immunol. 184:4557–4567. 2010. View Article : Google Scholar : PubMed/NCBI
13	Andrulis M, Penzel R, Weichert W, von Deimling A and Capper D: Application of a BRAF V600E mutation-specific antibody for the diagnosis of hairy cell leukemia. Am J Surg Pathol. 36:1796–800. 2012. View Article : Google Scholar : PubMed/NCBI
14	Kudo K, Ohga S, Morimoto A, et al: Improved outcome of refractory Langerhans cell histiocytosis in children with hematopoietic stem cell transplantation in Japan. Bone Marrow Transplant. 45:901–906. 2010. View Article : Google Scholar : PubMed/NCBI
15	Falchook GS, Long GV, Kurzrock R, et al: Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial. Lancet. 379:1893–1901. 2012. View Article : Google Scholar : PubMed/NCBI
16	Chapman PB, Hauschild A, Robert C, et al: Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 364:2507–2516. 2011. View Article : Google Scholar : PubMed/NCBI
17	Dietrich S, Glimm H, Andrulis M, von Kalle C, Ho AD and Zenz T: BRAF inhibition in refractory hairy-cell leukemia. N Engl J Med. 366:2038–2040. 2012. View Article : Google Scholar

Journals

International Journal of Molecular Medicine

International Journal of Oncology

Molecular Medicine Reports

Oncology Reports

Experimental and Therapeutic Medicine

Oncology Letters

Biomedical Reports

Molecular and Clinical Oncology

World Academy of Sciences Journal

International Journal of Functional Nutrition

International Journal of Epigenetics

Medicine International

Frequent BRAFV600E mutation has no effect on tumor invasiveness in patients with Langerhans cell histiocytosis

This article is mentioned in:

Abstract

Related Articles